Synthesis, Activity, and Pharmacophore Development for Isatin-β-thiosemicarbazones with Selective Activity toward Multidrug-Resistant Cells

被引：152

作者：

Hall, Matthew D. ^{[1
]}

Salam, Noeris K. ^{[2
]}

Hellawell, Jennifer L. ^{[1
]}

Fales, Henry M. ^{[3
]}

Kensler, Caroline B. ^{[3
]}

Ludwig, Joseph A. ^{[4
]}

Szakacs, Gergely ^{[5
]}

Hibbs, David E. ^{[2
]}

Gottesman, Michael M. ^{[1
]}

机构：

[1] NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA

[2] Univ Sydney, Fac Pharm, Pharmaceut Chem Div, Grp Biomol Struct & Informat, Sydney, NSW 2006, Australia

[3] NHLBI, Lab Appl Mass Spectrometry, NIH, Bethesda, MD 20892 USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Sarcoma Med Oncol, Houston, TX 77030 USA

[5] Hungarian Acad Sci, Inst Enzymol, H-1113 Budapest, Hungary

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2009年 / 52卷 / 10期

基金：

美国国家卫生研究院; 澳大利亚研究理事会;

关键词：

PRIMARY CYTOTOXICITY EVALUATION; RIBONUCLEOTIDE REDUCTASE; 3-AMINOPYRIDINE-2-CARBOXALDEHYDE THIOSEMICARBAZONE; IRON CHELATORS; PHASE-I; CANCER; INHIBITOR; DISCOVERY; TRANSPORTERS; DERIVATIVES;

D O I：

10.1021/jm800861c

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

We have recently identified a new class of compounds that selectively kill cells that express P-glycoprotein (P-gp, MDR1), the ATPase efflux pump that confers multidrug resistance on cancer cells. Several isatin-beta-thiosemicarbazones from our initial study have been validated and a range of analogues synthesized and tested. A number demonstrated improved MDR1-selective activity over the lead, NSC73306 (1). Pharmacophores for cytotoxicity and MDR1 selectivity were generated to delineate the structural features required for activity. The MDR1-selective pharmacophore highlights the importance of aromatic/hydrophobic features at the N4 position of the thiosemicarbazone and the reliance on the isatin moiety as key bioisosteric contributors. Additionally, a quantitative structure-activity relationship (QSAR) model that yielded a cross-validated correlation coefficient of 0.85 effectively predicts the cytotoxicity of untested thiosemicarbazones. Together, the models serve as effective approaches for predicting structures with MDR1-selective activity and aid in directing the search for the mechanism of action of 1.

引用

页码：3191 / 3204

页数：14

共 45 条

[21] The evolution of iron chelators for the treatment of iron overload disease and cancer
Kalinowski, DS
Richardson, DR
[J]. PHARMACOLOGICAL REVIEWS, 2005, 57 (04) : 547 - 583
[22] Synthesis and primary cytotoxicity evaluation of new 5-nitroindole-2,3-dione derivatives
Karali, N
[J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2002, 37 (11) : 909 - 918
[23] Karali N, 2002, ARCH PHARM, V335, P374, DOI 10.1002/1521-4184(200211)335:8<374::AID-ARDP374>3.0.CO
[24] 2-K
[25] Kingston DGI, 2005, CURR OPIN DRUG DISC, V8, P207
[26] 2-ACETYLPYRIDINE THIOSEMICARBAZONES .1. NEW CLASS OF POTENTIAL ANTI-MALARIAL AGENTS
KLAYMAN, DL
BARTOSEVICH, JF
GRIFFIN, TS
MASON, CJ
SCOVILL, JP
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 1979, 22 (07) : 855 - 862
[27] Laird AD, 2000, CANCER RES, V60, P4152
[28] Leonard Gregory D, 2002, Curr Opin Investig Drugs, V3, P1652
[29] INHIBITION OF RNA-DEPENDENT DNA POLYMERASE OF ROUS-SARCOMA VIRUS BY THIOSEMICARBAZONES AND SEVERAL CATIONS
LEVINSON, W
FARAS, A
WOODSON, B
JACKSON, J
BISHOP, JM
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1973, 70 (01) : 164 - 168
[30] Liu M C, 1995, Prog Med Chem, V32, P1

← 1 2 3 4 5 →